Responses were observed with cabozantinib, vandetanib, sunitinib, lenvatinib, and nintedanib, but not with sorafenib, alectinib, ponatinib, or regorafenib (Table 2)….Response to therapy was noted in three patients with non-KIF5B fusion partners, including two with CCDC6-RET...

In the subgroup analysis according to the type of RET fusion, median PFS and OS were 2.9 months (95% CI 1.1-15.7) and 10.5 months (95% CI 3.0-18.1) in patients with KIF5B-RET whereas 8.4 (95% CI 4.7-not reached [NR]) and NR (95% CI 9.9-NR) in those with CCDC6-RET....results found that vandetanib to be effective in patients with advanced RET-rearranged NSCLC, and that RET rearrangement may be a favorable molecular subgroup of NSCLC suitable for targeted therapy.